Decheng Capital Management Iii (Cayman), LLC Aadi Bioscience, Inc. Transaction History
Decheng Capital Management Iii (Cayman), LLC
- $181 Million
- Q3 2023
A detailed history of Decheng Capital Management Iii (Cayman), LLC transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Decheng Capital Management Iii (Cayman), LLC holds 526,329 shares of AADI stock, worth $768,440. This represents 1.41% of its overall portfolio holdings.
Number of Shares
526,329
Previous 526,329
-0.0%
Holding current value
$768,440
Previous $3.6 Million
29.25%
% of portfolio
1.41%
Previous 1.91%
Shares
1 transactions
Others Institutions Holding AADI
# of Institutions
64Shares Held
13.7MCall Options Held
4.9KPut Options Held
700-
Avoro Capital Advisors LLC New York, NY2.85MShares$4.16 Million0.08% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$2.7 Million3.54% of portfolio
-
Satter Management Co., L.P.1.63MShares$2.38 Million4.26% of portfolio
-
Black Rock Inc. New York, NY1.04MShares$1.52 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA857KShares$1.25 Million0.0% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $30.7M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...